Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

Study

BHV-3000-201

Treatment

Rimegepant

Mean age (years)

43.2

Female (%)

91.1%

Mean MMD at baseline (mean)

10.9

  1. MMD monthly migraine day